Definium Therapeutics’ shares rise sharply Monday after the company reports that its LSD-based experimental depression treatment, DT120, meets a key trial goal. Bloomberg and other outlets report that the stock climbs by roughly 55–60% in early trading, reflecting investor reaction to the trial results. Definium says DT120 reduces symptoms of major depressive disorder by 8.1 points more than placebo after six weeks, based on a standard depression score used in the study. The company also reports that patients show improvement within one week after a single dose, with benefits observed to persist through 12 weeks. Reports agree that the treatment is generally well tolerated, with mostly mild side effects concentrated around dosing day and no serious safety concerns highlighted in the available summaries. The trial includes 149 adults with major depressive disorder. Sources also note that recent U.S. policy initiatives are encouraging faster development of psychedelic-based mental health treatments, providing a favorable regulatory backdrop for companies in the sector.
Definium shares jump after LSD-based depression drug reports late-stage trial success
Key Points
- Definium Therapeutics’ stock jumps about 55–60% in Monday trading after trial results are announced.
- DT120, an LSD-based experimental drug for major depressive disorder, meets a main clinical trial goal.
- After six weeks, DT120 reduces depression symptoms by 8.1 points more than placebo.
- Patients show improvement within one week after a single dose, with benefits reported through 12 weeks.
- The treatment is reported as generally well tolerated, with mostly mild side effects and no serious safety concerns noted.
3 sources
4 months ago
44 views
This summary is generated automatically from the reporting of the outlets listed on this page. Follow their links for the full coverage.
How Outlets Covered This Story
Related Stories
Angela Constance orders review amid NHS Grampian concerns and cover-up allegations
Angela Constance, Scotland’s Health Secretary, responds to allegations of a cover-up at NHS Grampian by announcing an in...
3 sources
1 hour ago
UK pharmacist warns against using weekly pill organisers incorrectly
A UK pharmacist issues a warning about how people use daily or weekly pill organisers, saying the practice could undermi...
2 sources
8 hours ago
Gordon Ramsay’s morning drink routine linked to lower cancer risk
Gordon Ramsay’s morning drink routine is being discussed after outlets reported that the habit could be associated with...
2 sources
9 hours ago